PCR Journal Club

This is a trial aiming to assess QFR and 3D-QCA DS% of all the non-infarct related arteries (IRA) with 3D-QCA DS% in all patients presenting with STEMI/NSTEMI and undergoing coronary angiography. 

This patient-level analysis of randomized trials comparing PCI vs CABG for the treatment of low-to-intermediate CAD involving the LM confirms the absence of long-term differences in mortality between revascularization techniques, regardless of the clinical presentation.

This is the largest real world observational data that confirms the safety and efficacy of TAVR for the treatment of patients with severe aortic stenosis presenting with cardiogenic shock. 

While the choice between PCI and CABG for LMCA disease continues to be one of the most controversial topics, patient characteristics & comorbidities must be taken into account, as must the external validity of the results of RCTs in the real world, as the SWEDEHEART registry does.

The single-arm BIVOLUTX registry provides an accurate picture of contemporary practice and clinical outcomes of TAVI in BAV patients with AS, adding valuable prospective evidence to the field.

The investigator initiated, multicentre, randomised, EBC TWO trial compared a provisional strategy with a systematic culotte technique in patients with true non-LMS bifurcation disease. At one year, there was no difference between the groups in terms of the composite endpoint of all-cause mortality, MI or TVR....

Provisional stenting (PS) is the default approach for treating most coronary bifurcation lesions (CBL). The side branch (SB) can be compromised after main vessel (MV) stenting in up to 6-18 % of cases. The 17th Expert consensus document of the European Bifurcation Club details strategies for...

The aim of the b-RIGHT study was to assess the safety and performance of T-TEER using the TriClip (Abbott) in a contemporary, real-world setting...

This study challenges the double-jeopardy assumption as the main cause of adverse outcome in STEMI with non-IRA CTO, as a collateral origin distal from the acute IRA occlusion was associated with a significantly better prognosis than with a proximal origin.

The 12-month outcomes of the BIOMAG-I first-in-human trial demonstrate a favorable safety profile for the third-generation magnesium scaffold and 38 % improved performance compared to its precursor.